223 related articles for article (PubMed ID: 35970303)
1. Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy.
Lee D; Jordan AI; Menges MA; Lazaryan A; Nishihori T; Gaballa SR; Shah BD; Pinilla-Ibarz J; Baluch A; Klinkova OV; Chavez JC; Jain MD; Locke FL
Transplant Cell Ther; 2023 Apr; 29(4):277.e1-277.e9. PubMed ID: 35970303
[TBL] [Abstract][Full Text] [Related]
2. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
[TBL] [Abstract][Full Text] [Related]
3. Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients.
Oesterreich S; Lindemann M; Goldblatt D; Horn PA; Wilde B; Witzke O
Vaccine; 2020 Apr; 38(17):3339-3350. PubMed ID: 32178906
[TBL] [Abstract][Full Text] [Related]
4. The 13-Valent Pneumococcal Conjugate Vaccine Elicits Serological Response and Lasting Protection in Selected Patients With Primary Humoral Immunodeficiency.
Robbins A; Bahuaud M; Hentzien M; Maestraggi Q; Barbe C; Giusti D; Le Naour R; Batteux F; Servettaz A
Front Immunol; 2021; 12():697128. PubMed ID: 34290713
[TBL] [Abstract][Full Text] [Related]
5. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
[TBL] [Abstract][Full Text] [Related]
7. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.
Millar EV; O'Brien KL; Bronsdon MA; Madore D; Hackell JG; Reid R; Santosham M
Clin Infect Dis; 2007 May; 44(9):1173-9. PubMed ID: 17407035
[TBL] [Abstract][Full Text] [Related]
8. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
[TBL] [Abstract][Full Text] [Related]
9. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
[TBL] [Abstract][Full Text] [Related]
10. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B;
Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients.
Hung TY; Kotecha RS; Blyth CC; Steed SK; Thornton RB; Ryan AL; Cole CH; Richmond PC
Cancer; 2017 Nov; 123(21):4215-4223. PubMed ID: 28696530
[TBL] [Abstract][Full Text] [Related]
13. Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV - Immunological Response and Protection.
Romaru J; Bahuaud M; Lejeune G; Hentzien M; Berger JL; Robbins A; Lebrun D; N'Guyen Y; Bani-Sadr F; Batteux F; Servettaz A
Front Immunol; 2021; 12():791147. PubMed ID: 34987514
[TBL] [Abstract][Full Text] [Related]
14. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.
Pasiarski M; Rolinski J; Grywalska E; Stelmach-Goldys A; Korona-Glowniak I; Gozdz S; Hus I; Malm A
PLoS One; 2014; 9(12):e114966. PubMed ID: 25506837
[TBL] [Abstract][Full Text] [Related]
15. Persistence of pneumococcal antibodies after primary immunisation with a polysaccharide-protein conjugate vaccine.
Zimmermann P; Perrett KP; Berbers G; Curtis N
Arch Dis Child; 2019 Jul; 104(7):680-684. PubMed ID: 30796020
[TBL] [Abstract][Full Text] [Related]
16. Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia.
Takeshita K; Takeuchi N; Takahashi Y; Fukasawa C; Hishiki H; Hoshino T; Ishiwada N; Shimojo N
Hum Vaccin Immunother; 2021 Oct; 17(10):3687-3691. PubMed ID: 34213395
[TBL] [Abstract][Full Text] [Related]
17. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
Lupinacci R; Rupp R; Wittawatmongkol O; Jones J; Quinones J; Ulukol B; Dagan R; Richmond P; Stek JE; Romero L; Koseoglu S; Tamms G; McFetridge R; Li J; Cheon K; Musey L; Banniettis N; Bickham K;
Vaccine; 2023 Jan; 41(5):1142-1152. PubMed ID: 36621410
[TBL] [Abstract][Full Text] [Related]
18. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
Platt HL; Cardona JF; Haranaka M; Schwartz HI; Narejos Perez S; Dowell A; Chang CJ; Dagan R; Tamms GM; Sterling T; Morgan L; Shi Y; Pedley A; Musey LK; Buchwald UK
Vaccine; 2022 Jan; 40(1):162-172. PubMed ID: 34507861
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
[TBL] [Abstract][Full Text] [Related]
20. Pneumococcal conjugate vaccination response in patients after community-acquired pneumonia, differences in patients with S. pneumoniae versus other pathogens.
Wagenvoort GHJ; Vlaminckx BJM; van Kessel DA; Geever RCL; de Jong BAW; Grutters JC; Bos WJW; Meek B; Rijkers GT
Vaccine; 2017 Sep; 35(37):4886-4895. PubMed ID: 28802755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]